Short Interest in BioNxt Solutions Inc. (OTCMKTS:BNXTF) Declines By 63.2%

Key Points

• Short interest in BioNxt Solutions Inc. has decreased by 63.2%, falling to 1,400 shares as of September 15th from 3,800 shares at the end of August.
• The company reported earnings of ($0.01) per share for the quarter ending August 28th and has a market capitalization of $71.77 million.
• BioNxt Solutions is involved in developing drug formulations and delivery systems in multiple countries, including transdermal patches and oral biosensors for various medical applications.

BioNxt Solutions Inc. (OTCMKTS:BNXTF - Get Free Report) was the recipient of a large decline in short interest in September. As of September 15th, there was short interest totaling 1,400 shares, a decline of 63.2% from the August 31st total of 3,800 shares. Based on an average daily trading volume, of 2,300 shares, the days-to-cover ratio is currently 0.6 days. Based on an average daily trading volume, of 2,300 shares, the days-to-cover ratio is currently 0.6 days.

BioNxt Solutions Price Performance

Shares of OTCMKTS:BNXTF opened at $0.62 on Thursday. The company's 50-day moving average price is $0.63 and its two-hundred day moving average price is $0.46. The stock has a market capitalization of $71.77 million, a PE ratio of -15.50 and a beta of 0.80. BioNxt Solutions has a one year low of $0.16 and a one year high of $0.80.

BioNxt Solutions (OTCMKTS:BNXTF - Get Free Report) last issued its earnings results on Thursday, August 28th. The company reported ($0.01) earnings per share (EPS) for the quarter.

BioNxt Solutions Company Profile

BioNxt Solutions Inc engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.